Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Approvals Action
Janssen's new biologic approved
Will challenge Humira for lucrative psoriasis market, plus new indication for Novartis drug.
Pipeline Monitor
Keytruda chases 14th indication
Cervical cancer next on the IO blockbuster's list.
What's behind MA's CEO problem?
Board needs to ask questions over vanishing secretariat leaders.